• guangyi.chen@helmholtz-hips.de

Master’s degree in Bioinformatics from Saarland University, Germany. He started as a PhD student in Drug Bioinformatics group in HIPS from 2022. His research aims to develop a novel therapeutic approach

• mayukh.bhattacharyya@helmholtz-hips.de

LTM-produced antibiotics, as well as potential effects on the microbiome, toxicity, immune response, and drug metabolism.

• simone.rosinus@helmholtz-hips.de
• +49 68198806-4860

product antibiotics, the investigation of pharmacokinetics, and the assessment of synergistic effects of drug combinations. She is also working on the validation of screening tools and the chemical optimization

• angela.sester@helmholtz-hips.de
• +49-681-98806-5520

Dortmund University under Prof. Dr. Markus Nett, where she mainly investigated myxobacteria for new drug classes. As a postdoc at the TU Dresden with Prof. Dr. Tobias A. M. Gulder, the research focus shifted

• sidra.eisa@helmholtz-hips.de
• +49 6819 8806-2052

Later, she pursued her PhD at HIPS under the supervision of Prof. Anna Hirsch at the Department of Drug Design and Optimization, working on the synthesis of novel inhibitors targeting underexplored bacterial

• Xiaoqi.ji@helmholtz-hips.de
• +49 1520571388

research focuses on enzyme catalysis, natural product biosynthesis, and sustainable strategies for drug discovery.

• qingyuan.liu@helmholtz-hips.de

generative models to design novel protein sequences and applies explainable AI (XAI) techniques to Drug-Target Interaction (DTI) models. These efforts aim to identify critical protein residues, enabling